Newman Michael James
Known title: CSO and DirectorCIK: 0001876315
Associated companies
Transaction History
| INDP | ▲ Buy | Grant | 52,204 | $106K | 12/22/2025 | View on chart |
| INDP | ▼ Sell | Open Market | 14,130 | $71K | 2/1/2022 | View on chart |
| INDP | ▼ Sell | Open Market | 5,870 | $29K | 1/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Indaptus named among top small-cap healthcare performers
Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.
Indaptus named among top small-cap healthcare performers. Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.